Lymphoma, Non-Hodgkin, Familial disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LYM143 MIFTS: 72	Lymphoma, Non-Hodgkin, Familial Categories: Genetic diseases, Cancer diseases, Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Lymphoma, Non-Hodgkin, Familial

MalaCards integrated aliases for Lymphoma, Non-Hodgkin, Familial:

Name: Lymphoma, Non-Hodgkin, Familial ⁵⁷ ³⁸ ⁴⁰

Non-Hodgkin Lymphoma ⁵⁷ ³⁸ ¹² ⁷⁶ ¹⁵

Lymphoma, Non-Hodgkin ⁵⁷ ¹³ ⁷³

Nhl ⁵⁷ ⁷⁵

Lymphoma, Non-Hodgkin, Somatic ⁵⁷

Lymphoma, Follicular, Somatic ⁵⁷

Familial Non-Hodgkin Lymphoma ⁷⁵

Non-Hodgkin Lymphoma; Nhl ⁵⁷

Lymphoma Non-Hodgkins ⁵⁵

Classifications:

MalaCards categories:
Global: Genetic diseases Cancer diseases
Anatomical: Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Other and unspecified types of non-Hodgkin lymphoma

Other specified types of non-Hodgkin lymphoma

External Ids:

OMIM ⁵⁷ 605027

Disease Ontology ¹² DOID:0060060

MedGen ⁴² C0024305

ICD10 ³³ C85.7

SNOMED-CT via HPO ⁶⁹ 115244002 118600007 188676008 more

Sources

Summaries for Lymphoma, Non-Hodgkin, Familial

UniProtKB/Swiss-Prot : ⁷⁵ Familial non-Hodgkin lymphoma: Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.

MalaCards based summary : Lymphoma, Non-Hodgkin, Familial, also known as non-hodgkin lymphoma, is related to lymphoma, hodgkin, classic and lymphoma. An important gene associated with Lymphoma, Non-Hodgkin, Familial is CASP10 (Caspase 10), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Mozobil and Rituxan have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are lymphoma and Decreased viability in esophageal squamous lineage

Disease Ontology : ¹² A lymphoma that is characterized as any kind of lymphoma except Hodgkin's lymphoma.

Wikipedia : ⁷⁶ Non-Hodgkin lymphoma (NHL) is a group of blood cancers that includes all types of lymphoma except... more...

Description from OMIM: 605027

Sources

Related Diseases for Lymphoma, Non-Hodgkin, Familial

Diseases related to Lymphoma, Non-Hodgkin, Familial via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)

#	Related Disease	Score	Top Affiliating Genes
1	lymphoma, hodgkin, classic	33.0	ALK BCL6 PAX5 PTPRC
2	lymphoma	32.9	ALK BCL10 BCL6 CASP10 CCND1 MALT1
3	mantle cell lymphoma	32.2	BCL6 CCND1 CD5 MALT1 MYC PAX5
4	non-hodgkin lymphoma, during pregnancy	12.3
5	non-hodgkin lymphoma, childhood	12.2
6	cll/sll	11.5	CCND1 CD5 PAX5 TP53
7	bladder urothelial carcinoma	11.5	BRAF CCND1 NRAS PIK3CA TP53
8	nodular lymphocyte predominant hodgkin lymphoma	11.5	BCL6 CCND1 PAX5 PTPRC
9	epidural neoplasm	11.5	BCL6 CD5 PTPRC TP53
10	ovarian serous cystadenocarcinoma	11.5	BRAF NRAS PIK3CA TP53
11	b cell prolymphocytic leukemia	11.5	CD5 MS4A1 MYC TP53
12	respiratory system cancer	11.5	ALK CCND1 MYC PIK3CA TP53
13	peripheral nervous system neoplasm	11.5	ALK MYC NRAS TP53
14	cell type cancer	11.5	ALK CCND1 MYC NRAS TP53
15	autonomic nervous system neoplasm	11.5	ALK MYC NRAS TP53
16	colon lymphoma	11.5	ALK BCL6 CD5 PTPRC
17	renal cell carcinoma, papillary, 1	11.5	BRAF NRAS PIK3CA TP53
18	mature b-cell neoplasm	11.5	BCL6 MYC PTPRC TP53
19	breast lymphoma	11.5	ALK BCL6 CD5
20	non-proliferative fibrocystic change of the breast	11.5	CCND1 NPM1 TP53
21	myeloma, multiple	11.5	BRAF CCND1 MYC NRAS PTPRC TP53
22	peripheral t-cell lymphoma	11.5	ALK BCL6 CD5 MS4A1 TP53
23	lymphoma, mucosa-associated lymphoid type	11.5	BCL10 BCL6 CCND1 CD5 MALT1
24	female reproductive organ cancer	11.5	CCND1 MYC PIK3CA TP53
25	differentiated thyroid carcinoma	11.5	ALK BRAF NRAS TP53
26	lung cancer susceptibility 3	11.5	ALK BRAF CCND1 NRAS PIK3CA TP53
27	bile duct carcinoma	11.5	CCND1 MYC PIK3CA TP53
28	inflammatory myofibroblastic tumor	11.5	ALK CCND1 NPM1 TP53
29	marginal zone b-cell lymphoma	11.5	BCL10 BCL6 CD5 MALT1
30	erdheim-chester disease	11.5	BRAF NRAS PIK3CA
31	adamantinoma of long bones	11.5	BRAF CCND1 MYC PIK3CA TP53
32	plasmablastic lymphoma	11.5	BCL6 MS4A1 MYC PTPRC
33	gastric adenocarcinoma	11.5	BRAF CCND1 MYC NRAS PIK3CA TP53
34	reticulosarcoma	11.5	ALK BCL6 NPM1 PAX5 PTPRC
35	lung lymphoma	11.5	ALK BCL6 CD5 MALT1 PAX5
36	follicular lymphoma	11.5	BCL10 BCL6 CCND1 MS4A1 MYC
37	splenic marginal zone lymphoma	11.5	BCL6 CD5 MALT1 PAX5
38	glioblastoma	11.5	ALK BRAF CCND1 MYC NRAS PIK3CA
39	adrenocortical carcinoma, hereditary	11.5	BRAF NRAS PIK3CA TP53
40	hodgkin's lymphoma, lymphocytic depletion	11.5	ALK PAX5 PTPRC
41	primary cutaneous anaplastic large cell lymphoma	11.5	ALK NPM1 PTPRC
42	diffuse large b-cell lymphoma	11.4	ALK BCL10 BCL6 CD5 MALT1 MYC
43	composite lymphoma	11.4	BCL6 CD5 PAX5
44	gastric lymphoma	11.4	BCL10 BCL6 TP53
45	hemimegalencephaly	11.4	CCND1 MYC PIK3CA
46	gastrointestinal system cancer	11.4	CCND1 MYC PIK3CA TP53
47	lymphatic system cancer	11.4	ALK BCL6 CD5 MYC NPM1 PTPRC
48	brain cancer	11.4	ALK BRAF NRAS PIK3CA TP53
49	autoimmune lymphoproliferative syndrome	11.4	CASP10 NRAS PRF1 PTPRC
50	esophagus adenocarcinoma	11.4	MYC PIK3CA TP53

Graphical network of the top 20 diseases related to Lymphoma, Non-Hodgkin, Familial:

Sources

Symptoms & Phenotypes for Lymphoma, Non-Hodgkin, Familial

Clinical features from OMIM:

605027

Human phenotypes related to Lymphoma, Non-Hodgkin, Familial:

³²

#	Description	HPO Frequency	HPO Source Accession
1	lymphoma ³²		HP:0002665

GenomeRNAi Phenotypes related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability in esophageal squamous lineage	GR00235-A	9.85	PIK3CA PTPRC RAD54L TP53 BCL10 BCL6
2	Reduced mammosphere formation	GR00396-S	9.5	BCL6 BRAF CCND1 CD5 MYC NRAS
3	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.44	BCL10 MALT1 RAD54B RAD54L TP53
4	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.44	BCL10 BRAF CCND1 MALT1 MYC RAD54B

MGI Mouse Phenotypes related to Lymphoma, Non-Hodgkin, Familial:

⁴⁶ (show all 15)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system	MP:0005397	10.41	BCL10 BCL6 BRAF CCND1 CD5 MALT1
2	cellular	MP:0005384	10.39	BCL10 BCL6 BRAF CCND1 MYC NPM1
3	immune system	MP:0005387	10.38	PAX5 PIK3CA PRF1 PTPRC RAD54L TP53
4	mortality/aging	MP:0010768	10.31	RAD54B RAD54L TP53 PRF1 PTPRC ALK
5	growth/size/body region	MP:0005378	10.3	ALK BCL6 BRAF CCND1 MYC NPM1
6	endocrine/exocrine gland	MP:0005379	10.28	PTPRC TP53 ALK BCL10 BCL6 BRAF
7	homeostasis/metabolism	MP:0005376	10.27	ALK BCL6 BRAF CCND1 MYC NRAS
8	integument	MP:0010771	10.16	ALK BRAF CCND1 CD5 MYC NPM1
9	neoplasm	MP:0002006	10.11	ALK BRAF CCND1 MYC NPM1 NRAS
10	nervous system	MP:0003631	10.1	PAX5 ALK BCL10 BRAF CCND1 CD5
11	liver/biliary system	MP:0005370	10.03	BCL6 BRAF MYC NPM1 NRAS PRF1
12	normal	MP:0002873	9.85	BCL6 BRAF CCND1 CD5 MYC NRAS
13	no phenotypic analysis	MP:0003012	9.8	BCL6 CD5 MYC NRAS PIK3CA PTPRC
14	pigmentation	MP:0001186	9.35	ALK BRAF MYC NRAS TP53
15	skeleton	MP:0005390	9.28	MYC NRAS PAX5 PIK3CA PTPRC TP53

Sources

Drugs & Therapeutics for Lymphoma, Non-Hodgkin, Familial

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Mozobil ¹⁸ ⁴⁹	PLERIXAFOR	Genzyme	December 2008
FDA Label: Mozobil Disease/s that Drug Treats:non-Hodgkinâs lymphoma and multiple myeloma Indications and Usage: ¹⁸ Mozobil, a hematopoietic stem cell mobilizer, is indicated in combinationwith granulocyte-colony stimulating factor (G-CSF) to mobilizehematopoietic stem cells (HSCs) to the peripheral blood for collection andsubsequent autologous transplantation in patients with non-Hodgkinâslymphoma and multiple myeloma. (1) DrugBank Targets: ¹⁶ 1. C-X-C chemokine receptor type 4 Mechanism of Action: ¹⁸ Target: hematopoietic stem cell/ CXCR4 chemokine receptor Action: monilizer/ inhibitor FDA: Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognateligand, stromal cell-derived factor-1Î± (SDF-1Î±). SDF-1Î± and CXCR4 are recognized to play arole in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrowcompartment. Once in the marrow, stem cell CXCR4 can act to help anchor these cells to themarrow matrix, either directly via SDF-1Î± or through the induction of other adhesion molecules.Treatment with plerixafor resulted in leukocytosis and elevations in circulating hematopoieticprogenitor cells in mice, dogs and humans. CD34+ cells mobilized by plerixafor were capable ofengraftment with long-term repopulating capacity up to one year in canine transplantationmodels.
2	Rituxan ¹⁸ ⁴⁹	RITUXIMAB	Biogen IDEC, Genentech	November 1997
FDA Label: Rituxan Disease/s that Drug Treats:non-hodgkin's lymphoma Indications and Usage: ¹⁸ RituxanÂ® (rituximab) is a CD20-directed cytolytic antibody indicated for thetreatment of patients with: Non-Hodgkinâs Lymphoma (NHL) (1.1) Chronic Lymphocytic Leukemia (CLL) (1.2) Rheumatoid Arthritis (RA) in combination with methotrexate in adultpatients with moderately-to severely-active RA who have inadequateresponse to one or more TNF antagonist therapies (1.3) Granulomatosis with Polyangiitis (GPA) (Wegenerâs Granulomatosis) andMicroscopic Polyangiitis (MPA) in adult patients in combination withglucocorticoids (1.4)Limitations of Use: Rituxan is not recommended for use in patients withsevere, active infections (1.5). DrugBank Targets: ¹⁶ 1. Low affinity immunoglobulin gamma Fc region receptor III-B;2. Complement C1r subcomponent;3. Complement C1q subcomponent subunit A;4. Complement C1q subcomponent subunit B;5. Complement C1q subcomponent subunit C;6. Low affinity immunoglobulin gamma Fc region receptor III-A;7. Complement C1s subcomponent;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c;12. B-lymphocyte antigen CD20 Mechanism of Action: ¹⁸ Target: CD20 antigen expressed on the surface ofpre-B and mature B-lymphocytes Action: mediator of B-cell lysis through different possible types of cytotoxicity FDA: Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the surface ofpre-B and mature B-lymphocytes. Upon binding to CD20, rituximab mediates B-cell lysis. Possiblemechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependentcell mediated cytotoxicity (ADCC). The antibody induced apoptosis in the DHL 4 human B celllymphoma cell line.B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associatedchronic synovitis. In this setting, B cells may be acting at multiple sites in theautoimmune/inflammatory process, including through production of rheumatoid factor (RF) andother autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokineproduction.
3	Treanda ¹⁸ ⁴⁹	BENDAMUSTINE HYDROCHLORIDE	Cephalon	October 2008
FDA Label: Treanda Disease/s that Drug Treats:Chronic lymphocytic leukemia and B-cell non-Hodgkinâs lymphoma Indications and Usage: ¹⁸ TREANDA is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first linetherapies other than chlorambucil has not been established. (1.1) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed duringor within six months of treatment with rituximab or a rituximab-containingregimen. (1.2) DrugBank Targets: - Mechanism of Action: ¹⁸ Target: - Action: - FDA: Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring.Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electronrichnucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to celldeath via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism ofaction of bendamustine remains unknown.
4	Zevalin ¹⁸ ⁴⁹	IBRITUMOMAB TIUXETAN	Biogen IDEC	February 2002
FDA Label: Zevalin Disease/s that Drug Treats:Non-Hodgkin's lymphoma Indications and Usage: ¹⁸ Zevalin is a CD20-directed radiotherapeutic antibody administered as part ofthe Zevalin therapeutic regimen indicated for the treatment of patients with: relapsed or refractory, low-grade or follicular B-cell non-Hodgkin'slymphoma (NHL) (1.1). previously untreated follicular NHL who achieve a partial or completeresponse to first-line chemotherapy (1.2). DrugBank Targets: ¹⁶ 1. B-lymphocyte antigen CD20;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. Complement C1s subcomponent;9. High affinity immunoglobulin gamma Fc receptor I;10. Low affinity immunoglobulin gamma Fc region receptor II-a;11. Low affinity immunoglobulin gamma Fc region receptor II-b;12. Low affinity immunoglobulin gamma Fc region receptor II-c Mechanism of Action: ¹⁸ Target: CD20 antigen --> Y-90 Action: beta emission causes damage FDA: Ibritumomab tiuxetan binds specifically to the CD20 antigen (human B-lymphocyte-restricted differentiation antigen,Bp35). The apparent affinity (KD) of ibritumomab tiuxetan for the CD20 antigen ranges between approximately 14 to18 nM. The CD20 antigen is expressed on pre-B and mature B lymphocytes and on > 90% of B-cell non-Hodgkinâslymphomas (NHL). The CD20 antigen is not shed from the cell surface and does not internalize upon antibody binding.The chelate tiuxetan, which tightly binds Y-90, is covalently linked to ibritumomab. The beta emission from Y-90induces cellular damage by the formation of free radicals in the target and neighboring cells.Ibritumomab tiuxetan binding was observed in vitro on lymphoid cells of the bone marrow, lymph node, thymus, red andwhite pulp of the spleen, and lymphoid follicles of the tonsil, as well as lymphoid nodules of other organs such as thelarge and small intestines.
5	Zydelig ¹⁸ ⁴⁹	IDELALISIB	Gilead	July 2014
FDA Label: Zydelig Disease/s that Drug Treats:relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma Indications and Usage: ¹⁸ Zydelig is a kinase inhibitor indicated for the treatment of patients with: Relapsed chronic lymphocytic leukemia (CLL), in combination withrituximab, in patients for whom rituximab alone would be consideredappropriate therapy due to other co-morbidities. (1.1) Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patientswho have received at least two prior systemic therapies. (1.2) Relapsed small lymphocytic lymphoma (SLL) in patients who havereceived at least two prior systemic therapies. (1.3)Accelerated approval was granted for FL and SLL based on overallresponse rate. Improvement in patient survival or disease relatedsymptoms has not been established. Continued approval for theseindications may be contingent upon verification of clinical benefit inconfirmatory trials. DrugBank Targets: ¹⁶ 1. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (P110Î´) Mechanism of Action: ¹⁸ Target: PI3KÎ´ kinase Action: inhibitor FDA: Idelalisib is an inhibitor of PI3KÎ´ kinase, which is expressed in normal and malignant Bcells.Idelalisib induced apoptosis and inhibited proliferation in cell lines derived frommalignant B-cells and in primary tumor cells. Idelalisib inhibits several cell signalingpathways, including B-cell receptor (BCR) signaling and the CXCR4 and CXCR5signaling, which are involved in trafficking and homing of B-cells to the lymph nodes andbone marrow. Treatment of lymphoma cells with idelalisib resulted in inhibition ofchemotaxis and adhesion, and reduced cell viability.

Drugs for Lymphoma, Non-Hodgkin, Familial (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 668)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

50-18-0, 6055-19-2

2907

Cytarabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

147-94-4

6253

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

50-02-2

5743

Ifosfamide

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

3778-73-2

3690

Prednisone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

53-03-2

5865

rituximab

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

174722-31-7

10201696

Vincristine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

2068-78-2, 57-22-7

5978

Lenograstim

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

135968-09-1

Thiotepa

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

52-24-4

5453

Doxorubicin

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

23214-92-8

31703

Entecavir

Approved, Investigational

Phase 4,Phase 2,Not Applicable

142217-69-4

153941

Fludarabine

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

21679-14-1, 75607-67-9

30751

Vidarabine

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable

24356-66-9

32326 21704

Etoposide

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

33419-42-0

36462

Methotrexate

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

1959-05-2, 59-05-2

126941

Methylprednisolone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

83-43-2

6741

Prednisolone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

50-24-8

5755

Vindesine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

59917-39-4, 53643-48-4

40839

Melphalan

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

148-82-3

4053 460612

Cisplatin

Approved

Phase 4,Phase 3,Phase 2,Phase 1

15663-27-1

84093 441203 2767

Gemcitabine

Approved

Phase 4,Phase 3,Phase 2,Phase 1

95058-81-4

60750

Oxaliplatin

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

61825-94-3

5310940 9887054 43805 6857599

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

22916-47-8

4189

Angiotensin II

Approved, Investigational

Phase 4,Phase 1

68521-88-0, 4474-91-3, 11128-99-7

172198 65143

Valsartan

Approved, Investigational

Phase 4

137862-53-4

60846

Lidocaine

Approved, Vet_approved

Phase 4

137-58-6

3676

Nitric Oxide

Approved

Phase 4

10102-43-9

145068 160954

Nitrous oxide

Approved, Vet_approved

Phase 4

10024-97-2

948

Prilocaine

Approved

Phase 4

721-50-6

4906

Epirubicin

Approved

Phase 4,Phase 2,Phase 3,Phase 1

56420-45-2

41867

Everolimus

Approved

Phase 4,Phase 3,Phase 2,Phase 1

159351-69-6

6442177

Sirolimus

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

53123-88-9

5284616 6436030 46835353

Mechlorethamine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

51-75-2

4033

Ribavirin

Approved

Phase 4,Phase 3

36791-04-5

37542

Ledipasvir

Approved

Phase 4,Phase 2

1256388-51-8

67505836

Sofosbuvir

Approved

Phase 4,Phase 2

1190307-88-0

45375808

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

59-30-3

6037

leucovorin

Approved, Nutraceutical

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

58-05-9

143 6006

Doxil

Approved June 1999

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

31703

Pirarubicin

Investigational

Phase 4

72496-41-4

Alkylating Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antineoplastic Agents, Alkylating

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antirheumatic Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

BB 1101

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Dexamethasone acetate

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

1177-87-3

Immunosuppressive Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Isophosphamide mustard

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antilymphocyte Serum

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Adjuvants, Immunologic

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Anti-HIV Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2326)

#	Name	Status	NCT ID	Phase	Drugs
1	Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults	Unknown status	NCT00797810	Phase 4	Rituximab
2	Bone Marrow Transplantation in Treating Patients With Hematologic Cancer	Completed	NCT00003398	Phase 4	cyclophosphamide;thiotepa
3	Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms	Completed	NCT01164475	Phase 4	Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
4	MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.	Completed	NCT00430352	Phase 4	rituximab [MabThera/Rituxan]
5	An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)	Completed	NCT02782845	Phase 4	Chemotherapy;Immunochemotherapy;Pegfilgrastim
6	Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma	Completed	NCT00969462	Phase 4	Doxorubicin
7	Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B	Completed	NCT00926757	Phase 4	Entecavir prophylaxis;Therapeutic entecavir
8	Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma	Completed	NCT01124526	Phase 4	Rituximab Fludarabine Cyclophosphamide
9	Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma	Completed	NCT00090038	Phase 4	rituximab
10	Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma	Completed	NCT00168727	Phase 4	ibritumomab tiuxetan (Zevalin®)
11	Prevention of CHOP-induced Chronic Cardiotoxicity	Completed	NCT00162955	Phase 4	Valsartan
12	Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults	Completed	NCT00199082	Phase 4	Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
13	PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation	Completed	NCT00352703	Phase 4	Kepivance (Palifermin)
14	Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture	Completed	NCT00808171	Phase 4	Livopan;Livopan;EMLA
15	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer	Completed	NCT00277160	Phase 4	Neulasta (pegfilgrastim)
16	ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia	Completed	NCT00114348	Phase 4
17	To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma	Recruiting	NCT02585947	Phase 4	Tenofovir
18	PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia	Recruiting	NCT02996617	Phase 4	rhG-CSF regimen;Pegylated rhG-CSF regimen
19	Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.	Recruiting	NCT03279133	Phase 4	Ledipasvir 90mg/Sofosubvir 400mg
20	Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma	Active, not recruiting	NCT01180049	Phase 4	temsirolimus;temsirolimus
21	CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma	Active, not recruiting	NCT01746992	Phase 4	Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
22	A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B	Terminated	NCT02608060	Phase 4	Epoetin Beta
23	Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study	Terminated	NCT02717949	Phase 4	sofosbuvir/ledipasvir;sofosbuvir;Ribavirin
24	Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain	Unknown status	NCT01316744	Phase 3	ketamine hydrochloride
25	Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer	Unknown status	NCT00482716	Phase 3
26	Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia	Unknown status	NCT00445497	Phase 3	amoxicillin-clavulanate potassium;ciprofloxacin
27	Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma	Unknown status	NCT00003338	Phase 2, Phase 3
28	Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma	Unknown status	NCT00003337	Phase 3
29	Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia	Unknown status	NCT00020865	Phase 3	cefepime hydrochloride;levofloxacin
30	Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome	Unknown status	NCT00002989	Phase 3	busulfan;cyclophosphamide;idarubicin;melphalan
31	Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma	Unknown status	NCT00003924	Phase 3
32	Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma	Unknown status	NCT02722733	Phase 3	G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
33	Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma	Unknown status	NCT00129090	Phase 3	R-CHOEP 14 with 12x Rituximab
34	Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma	Unknown status	NCT00463463	Phase 3	90Yttrium Ibritumomab Tiuxetan (Zevalin)
35	A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma	Unknown status	NCT00078598	Phase 3	Rituximab or Iodine I 131 Tositumomab Therapy
36	Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma	Unknown status	NCT00053768	Phase 3	EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
37	Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma	Unknown status	NCT00052936	Phase 3	CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
38	Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma	Unknown status	NCT00003423	Phase 3	asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;prednisolone;thioguanine;vincristine sulfate
39	Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma	Unknown status	NCT00551239	Phase 3	fludarabine phosphate;pixantrone dimaleate
40	Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma	Unknown status	NCT00003639	Phase 3	chlorambucil;dexamethasone;idarubicin
41	Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma	Unknown status	NCT00028717	Phase 3	cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
42	Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma	Unknown status	NCT00017290	Phase 3	cyclophosphamide;prednisone;vincristine sulfate
43	Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma	Unknown status	NCT00003650	Phase 3	asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;vincristine sulfate
44	Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma	Unknown status	NCT00003728	Phase 3	asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
45	Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma	Unknown status	NCT00022685	Phase 3
46	Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma	Unknown status	NCT01570049	Phase 3	Bendamustine
47	Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma	Unknown status	NCT00003815	Phase 3	carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisolone;vincristine sulfate
48	Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma	Unknown status	NCT00091676	Phase 3
49	Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's Lymphoma	Unknown status	NCT00006250	Phase 3	chlorambucil;dexamethasone;fludarabine phosphate;mitoxantrone hydrochloride
50	High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma	Unknown status	NCT00003578	Phase 3	CHOP regimen;carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisone;vincristine sulfate

Search NIH Clinical Center for Lymphoma, Non-Hodgkin, Familial

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :

aldesleukin

bendamustine

carmustine

chlorambucil

cisplatin

cisplatin pwdr

cladribine

fludarabine

fludarabine phosphate

ifosfamide

lomustine

mercaptopurine

pegaspargase

procarbazine

procarbazine hydrochloride

sargramostim

vincristine

vincristine sulfate

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Lymphoma, Non-Hodgkin, Familial cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Lymphoma, Non-Hodgkin, Familial:

	Blood stem cell transplantation for hematological diseases
	Hematopoietic stem cells for treatment of hematologic malignancies
	Hematopoietic stem cells for treatment of non-Hodgkin's lymphoma
	StemEx

Embryonic/Adult Cultured Cells Related to Lymphoma, Non-Hodgkin, Familial:

	Peripheral blood-derived hematopoietic stem cells (family)
	Bone marrow-derived hematopoietic stem cells
	Peripheral blood-derived hematopoietic stem cells PMIDs: 21831743
	Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724

Sources

Genetic Tests for Lymphoma, Non-Hodgkin, Familial

Sources

Anatomical Context for Lymphoma, Non-Hodgkin, Familial

MalaCards organs/tissues related to Lymphoma, Non-Hodgkin, Familial:

⁴¹

B Cells, T Cells, Bone, Bone Marrow, Lymph Node, Nk Cells, Kidney

Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphoma, Non-Hodgkin, Familial:

#	Tissue Anatomical CompartmentCell	Relevance
1	Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells	Potential therapeutic candidate
2	Blood Peripheral Blood Mature B-Cells	Affected by disease

Sources

Publications for Lymphoma, Non-Hodgkin, Familial

Articles related to Lymphoma, Non-Hodgkin, Familial:

(show top 50) (show all 1356)

#	Title	Authors	Year
1	Obstructive jaundice as primary presentation of a stage IIE Non-Hodgkin lymphoma: A decision making process between advanced lymphoma and locally advanced/metastatic pancreatic adenocarcinoma. ( 29547849 )	Blouhos K....Hatzigeorgiadis A.	2018
2	Paraneoplastic pemphigus without detectable anti-plakin antibodies in a patient with non-Hodgkin lymphoma. ( 29143865 )	Moreno-Artero E....EspaA+a A.	2018
3	Calciphylaxis in a Patient With Non-Hodgkin Lymphoma: Case Report and Literature Review. ( 29478335 )	Morand M....Fernandes C.	2018
4	Primary Cardiac B-Non-Hodgkin Lymphoma Disguised as a Pacemaker Endocarditis. ( 29977733 )	FleiA9ner F....KA1hn C.	2018
5	Second primary cutaneous T-cell lymphoma in patients with non-Hodgkin lymphoma: a chicken-or-the-egg issue. ( 29047113 )	Kamel J.G....Amber K.T.	2018
6	Synchronous papillary thyroid cancer and non-Hodgkin lymphoma: Case report. ( 29419687 )	Popivanov G.I....Cirocchi R.	2018
7	Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand. ( 28332735 )	Intragumtornchai T....Warnnissorn N.	2018
8	Evaluation of the cytotoxic response mediated by perforin and granzyme B in patients with non-Hodgkin lymphoma. ( 28679297 )	Souza B.M.B....Moraes-Souza H.	2018
9	Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. ( 29978452 )	Chihara D....Cheah C.Y.	2018
10	Non-alcoholic Wernicke-Korsakoff syndrome heralding non-Hodgkin lymphoma progression. ( 29582179 )	De Falco A....de Falco F.A.	2018
11	Does Q fever contribute to pathogenesis of non-Hodgkin lymphoma? ( 29650494 )	David K.A....Evens A.M.	2018
12	Herpes simplex reactivation after photodynamic therapy for actinic cheilitis in a patient with Non-Hodgkin Lymphoma: a possible indication for prophylaxis. ( 29512976 )	Brumana M.B....Belloni Fortina A.	2018
13	A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy. ( 29259834 )	Jungmann S....Bauer T.T.	2017
14	The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma. ( 29257907 )	Rezahosseini O....Rezaei N.	2017
15	Learning from the Failures of Drug Discovery in B-Cell Non-Hodgkin Lymphomas and Perspectives for the Future: Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma as Two Ends of a Spectrum in Drug Development. ( 28494631 )	Kubuschok B....Trepel M.	2017
16	Targeting non-Hodgkin Lymphoma with Blinatumomab. ( 28532177 )	Sanders S....Stewart D.A.	2017
17	Haploidentical hematopoietic stem cell transplantation with myeloablative conditioning regimen could serve as an optional salvage therapy for younger patients with refractory or relapsed aggressive non-Hodgkin lymphoma. ( 28509575 )	Xiao X....Wu D.	2017
18	PI3KI'-selective and PI3KI+/I'-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. ( 28945111 )	Lampson B.L....Brown J.R.	2017
19	Pure sensory ganglionopathy as the first sign of relapse in non-Hodgkin lymphoma. ( 28507261 )	Hossack M....McClean J.	2017
20	Correlation of Patterns of Bone Marrow Infiltration and Biochemical factors in Non-Hodgkin Lymphoma. ( 28523057 )	Mazher N....Iqbal Z.	2017
21	Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma. ( 28685851 )	Chang T.W....Brewer J.D.	2017
22	Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review. ( 28112752 )	Damaj G....Gyan E.	2017
23	Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma. ( 28104689 )	Gayle S....Lichenstein H.	2017
24	Identification of a new HLA-A allele, HLA-A*02:07:09, in a Chinese non-Hodgkin lymphoma patient. ( 28677225 )	Wang B.J....Wu X.X.	2017
25	Associations between genetic variants in immunoregulatory genes and risk of non-Hodgkin lymphoma in a Chinese population. ( 28060727 )	Ye X....Fu H.	2017
26	Prevalence of hepatitis B and hepatitis C viral infections in various subtypes of B-cell non-Hodgkin lymphoma: confirmation of the association with splenic marginal zone lymphoma. ( 28362442 )	Xiong W....Yi S.	2017
27	Anti-Ma2-associated limbic encephalitis with coexisting chronic inflammatory demyelinating polyneuropathy in a patient with non-Hodgkin lymphoma: A case report. ( 28984777 )	Ju W....Yang Y.	2017
28	Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma. ( 28914567 )	Herting F....Klein C.	2017
29	Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma. ( 28491264 )	Abuodeh Y....Kim S.	2017
30	Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors. ( 28922087 )	Salz T....Johansen C.	2017
31	Novel Mutations in SH2D1A Gene in X-linked Lymphoproliferative Syndrome, Diagnosed After B-Cell Non-Hodgkin Lymphoma. ( 28267077 )	Sharapova S.O....Aleinikova O.V.	2017
32	Loss of Reelin suppresses cell survival and mobility in non-Hodgkin lymphoma. ( 28498462 )	Dou A....Liu J.	2017
33	Neurocognitive, psychosocial, and quality-of-life outcomes in adult survivors of childhood non-Hodgkin lymphoma. ( 28915338 )	Ehrhardt M.J....Krull K.R.	2017
34	Breast lymphoma in a patient with B-cell Non Hodgkin Lymphoma: A case report study. ( 28915427 )	Marinopoulos S....Dimitrakakis C.	2017
35	Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma. ( 27558232 )	Salem A.H....Wong S.L.	2017
36	Periodontal disease and risk of non-Hodgkin lymphoma in the Health Professionals Follow-Up Study. ( 27861844 )	Bertrand K.A....Michaud D.S.	2017
37	Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis. ( 28531181 )	Yuan T....Wang X.	2017
38	Intestinal perforation that developed after chemotherapy in a patient diagnosed with non-Hodgkin lymphoma: A case report and review of literature. ( 28898795 )	Tatar C....Arikan S.	2017
39	Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy. ( 28123744 )	Bowen R.C....Khong H.T.	2017
40	Non-Hodgkin lymphoma of multiple extranodal involvement seen on MRI, FDG PET-CT scans: A case report. ( 29137032 )	Wang S....Xu K.	2017
41	TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis. ( 28369138 )	Xu P....Chen B.	2017
42	Do polychlorinated biphenyls cause cancer? A systematic review and meta-analysis of epidemiological studies on risk of cutaneous melanoma and non-Hodgkin lymphoma. ( 28535466 )	Zani C....Donato F.	2017
43	Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma. ( 28061782 )	Oliveira C.C....Domingues M.A.	2017
44	Dietary fat intake and risk of non-Hodgkin lymphoma in 2 large prospective cohorts. ( 28659300 )	Bertrand K.A....Birmann B.M.	2017
45	Creation of a pediatric mature B-cell non-Hodgkin lymphoma cohort within the Pediatric Health Information System Database. ( 29059235 )	Citrin R....Aplenc R.	2017
46	Dietary inflammatory index and non-Hodgkin lymphoma risk in an Italian case-control study. ( 28503716 )	Shivappa N....Polesel J.	2017
47	Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis. ( 27943422 )	Adams H.J....Kwee T.C.	2017
48	Plasma DNA methylation of p16 and shp1 in patients with B cell non-Hodgkin lymphoma. ( 28210822 )	Ding K....Fu R.	2017
49	Novel B7-H4-mediated crosstalk between human non-Hodgkin lymphoma cells and tumor-associated macrophages leads to immune evasion via secretion of IL-6 and IL-10. ( 28246881 )	Che F....Wang L.	2017
50	Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy. ( 28498337 )	Kesavan M....Turner J.H.	2017

Sources

Genes for Lymphoma, Non-Hodgkin, Familial

Genes related to Lymphoma, Non-Hodgkin, Familial (8 elite genes):

(show top 50) (show all 98)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	CASP10	Caspase 10	Protein Coding	1205.96	Molecular basis known ⁵⁷ Pathogenic ⁶ Causative variation ⁷⁵ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	12010812 11973654 12010812 (more) 20025484
2	RAD54B	RAD54 Homolog B	Protein Coding	900	Molecular basis known ⁵⁷ Pathogenic ⁶	10362364
3	PRF1	Perforin 1	Protein Coding	900	Molecular basis known ⁵⁷ Pathogenic ⁶	10583959 12229880 15728124 (more) 16278825
4	RAD54L	RAD54 Like	Protein Coding	900	Molecular basis known ⁵⁷ Pathogenic ⁶	10362365
5	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	700	Pathogenic ⁶ Causative variation ⁷⁵	12960123 14612909
6	BCL10	B Cell CLL/Lymphoma 10	Protein Coding	573.08	Molecular basis known ⁵⁷ Susceptibility factor ⁵⁷ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	11425462 10665648 18346354 (more) 11372735 10803524 11748643
7	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	428.83	Pathogenic ⁶ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵
8	TP53	Tumor Protein P53	Protein Coding	425.52	Pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)	1565144
9	FAS-AS1	FAS Antisense RNA 1 It plays an important role in non-Hodgkin's lymphomas Dysfunction Pattern:	RNA Gene	150	Experimental evidence ³⁹	24811343
10	CCND1	Cyclin D1	Protein Coding	30.62	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	7795235 10622539 7534138 (more) 9001420 9846986 9028966 10941340 7540362 16001955 16321849 1757070 7670110 7531681 9573674 8172823 1485535 19137297 19225536 16783567 16023083 12411587 7545645 12474231 9548443 7579380 7981893 16624404 9551917 9376597 12011261 20038219 12846895 12683869 16925576 7753558 17722077 16093790 11863220 9200999 1290353
11	BCL6	B Cell CLL/Lymphoma 6	Protein Coding	29.68	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	7742550 10953971 16125304 (more) 7472775 17142954 11742039 8618443 15024721 7794763 16249378 10233393 8758205 16867873 15256116 12414651 8988030 8025268 8652841 9184180 8703825 8063612 16815642 16331266 11579468 11516111 10490843 9824206 9642131 9209377 9160681 7669745 15611930 12835729 9796700 17404575 14513282 12594230 12555064 12173331 10666217 9402330 11914273 11780315 11157493 11920179 9824205 9747876 9573674 7639334 8142643 15202519 11865059 10898795 10637510 7795234 16264183 16772123 11290603 9504630 9359519 9921651
12	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	28.5	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵
13	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	27.86	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	9174053 15938644 9121481 (more) 17694547 18670314 8122112 7824924 14569815 14506160 9763551 15852431 18974134
14	PAX5	Paired Box 5	Protein Coding	25.74	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	16648862 19100628 9694719 (more) 17016584 17717600 9722295 12360049 16968900 17717432 9850179 10556196 10071452 14676435
15	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	25.67	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	11343379 8574164 10602433 (more) 10323217 9563496 18754028 9088026 8580815 12745652 1493439 1485535 8043869 19670467 12594230 9364867 1457505 2200538 1764535 19844983 9573674 1342969 1769408 1387833 8615659 17701581 1352077 18981293
16	CD5	CD5 Molecule	Protein Coding	25.5	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	1370753 9615189 8744680
17	PTPRC	Protein Tyrosine Phosphatase, Receptor Type C	Protein Coding	24.72	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	1829834 1845482 1669003
18	NPM1	Nucleophosmin 1	Protein Coding	24.36	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	9121481 8122112 7824924 (more) 9174053
19	MS4A1	Membrane Spanning 4-Domains A1	Protein Coding	24.31	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	15944291 11924912 16367924 (more) 12411587 1449258 12894078 14632776 19276251
20	MALT1	MALT1 Paracaspase	Protein Coding	24.12	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	12560219 15598810
21	IRF4	Interferon Regulatory Factor 4	Protein Coding	24.12	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	19396635 19897031 12594241
22	BCL2	BCL2, Apoptosis Regulator	Protein Coding	23.41	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	15503680 11380403 9113013 (more) 1747446 8220159 15061204 15669024 8574164 7632955 9088026 8436340 9207459 8558921 8547651 7581933 7819053 8417786 19537891 9758366 9587934 11855781 9002964 11866986 2223650 10794603 1290353 8080035 7949096 8667654 8945612 8774139 1602814 1757070 16840203 15550595 11722998 9665466 9349233 8104532 18287262 17916949 17404107 11113864 9655306 9443038 9413633 11877091 16156855 15794866 15784299 11679800 10074891 8704213 8535193 7981893 7950302 8297731 15611930 10564590 9591044 7695015 8400801 8418370 1581893 9573674 8732086 7790118 7937722 8220113 1774956 2249898 17074584 16193090 9343323 7981903 7519826 8172820 1342969 1485535 1391959 9276187 15846077 15255171 15077178 10766396 8204892 1387833 1339299 1742726 18929412 12210808 9712423 9681218 7505024 1633729 16518606 15377339 7723399 11818669
23	CD19	CD19 Molecule	Protein Coding	23.38	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	1706642 7517719
24	IL2	Interleukin 2	Protein Coding	23.21	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	15148492 2043594 7530170 (more) 12478000 15073100 1504052 1727923 18256325 15595640 2305833 7493395 2249592 8334424 10585595 8374518 11565839 1405755 1634929 15447996 11477458 7654854 1868045 2036661 8523344 17889355 17145827 14695220 8831999 20193734 16690518 17198084 12580972 10706460 7693434 17697543 1568183 1827736 17026825 9457395 8907277 1635170 14502258 8181576 8968107 1391948 12623838 7578523 1831682 7773948 10689713
25	NCOR2	Nuclear Receptor Corepressor 2	Protein Coding	22.87	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	15930272 9753732 14581437 (more) 11694947 12634948 17387390 11694946 9369411
26	TNFRSF8	TNF Receptor Superfamily Member 8	Protein Coding	18.76	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	8055109 7982672 7564510 (more) 10793083 1849500 1850308 1329671 8204884 7591296 14692525 15189504 19760074 8833395 2173674 9206929 10628334 7875968 11862770 1330287 8781434 16533741 7745117
27	CSF3	Colony Stimulating Factor 3	Protein Coding	16.06	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	19233728 8908287 11920216 (more) 12629058 15654353 17177909 9006749 10975387 7540461 7692189 11091498 18594529 14979480 9213175 9181898 8598236 7507533 7684011 14556680 8691577 7541257 7563935 7543059 1381626 16646673 12196361 9053502 19167685 18567557 17994119 18794865 17582943 11007055 10761530 9605644 9562926 19816079 10731947 16930137 1702132 1375485 7686283 8759907 9638986 10706456 16585020 8864456 8928121 8733686 7540401 7535843 7530468 7517260 19834627 16863911 19811326 11896424 11813173 11091491 11019842 11019835 10561192 9829733 9037362 11106111 10793559 10350339 9737696 9658727 9166835 7516922 1699654 17324009 19135941 12406901 12436219 11797111 11732872 16525786 16533747 12886256 12478902 11466671 11239168 11342310 10813543 10197794 10791904 9369412 8649061 7539658 7524599 19597422 19483760 8982296 7543069 7539966 18669165 15550484
28	BCL3	B Cell CLL/Lymphoma 3	Protein Coding	13.63	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	2243504 15105810 12835724 (more) 8011990 16123212 15716244
29	B2M	Beta-2-Microglobulin	Protein Coding	12.86	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	10342582 8496627 16545870 (more) 1414221 9329587
30	CD40	CD40 Molecule	Protein Coding	11.99	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	7507299 9767448 19751723 (more) 7530508 1702326 9056740 8541553 8819071 9163608 16166310 17456057 19362983
31	CD52	CD52 Molecule	Protein Coding	11.93	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	11807632 9126378 8027367
32	GZMB	Granzyme B	Protein Coding	11.76	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	11594520
33	MCL1	MCL1, BCL2 Family Apoptosis Regulator	Protein Coding	11.68	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	9591044 15343511 8080035 (more) 11818669 8686741 17430669
34	IL2RA	Interleukin 2 Receptor Subunit Alpha	Protein Coding	11.67	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	9732831 7933620 8496627 (more) 9166099 1727208 9437500 15899555 7679589 8494993 1394062 8082082 2068535 7819101 8678534 9329587 12443879 2206570 8067207 7553687 11924909 16690518 7719243 1414221 11168504 8019399 8260527 18030581 9206929
35	BCL2L1	BCL2 Like 1	Protein Coding	11.56	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	11835337 17096886 16081784 (more) 8686741 14617792 8616083
36	CSF2	Colony Stimulating Factor 2	Protein Coding	11.43	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	15989703 1859894 7980802 (more) 8616084 9171066 7511017 10561192 16041313 1679155 8648384 7950158 14682115 2185337 9193361
37	CCND3	Cyclin D3	Protein Coding	11.37	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	11242797 16620575 12383214 (more) 11895902 12898595 12594230 9713342 15305377
38	CD38	CD38 Molecule	Protein Coding	11.24	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	9206929 1449258
39	TNFSF13B	TNF Superfamily Member 13b	Protein Coding	10.92	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	17026820 19291294 19383901 (more) 16497967 14978135
40	TNFRSF13C	TNF Receptor Superfamily Member 13C	Protein Coding	10.9	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	19258594 19291294
41	CD44	CD44 Molecule (Indian Blood Group)	Protein Coding	10.8	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	10342571 7525912 10425314 (more) 8459220 11263339 7537983 10979212 7511297 7513537 7630011 11472578 9067581 9111868 7504454 16116502 12484499 11863224 10349995 7545748 7553660 8960109 9231152 10023342 2201831
42	AICDA	Activation Induced Cytidine Deaminase	Protein Coding	10.79	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	15732141 12511417 12873980 (more) 19734146 18776814
43	FCGR3A	Fc Fragment Of IgG Receptor IIIa	Protein Coding	10.75	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	17650444
44	CD27	CD27 Molecule	Protein Coding	10.75	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	12685844 12743427 17456057
45	DNTT	DNA Nucleotidylexotransferase	Protein Coding	10.67	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	9343323
46	IL3	Interleukin 3	Protein Coding	10.37	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	8523344 9592981 18214283 (more) 8218491 14770420 9225366 7698300 8542941 8639889 8440338 8547077 9543065 10561192
47	FAS	Fas Cell Surface Death Receptor	Protein Coding	10.12	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	19751723 9531598 9787134 (more) 15160902 8741700 12804643 15757536 8774139 7572793 10492090 16628716 9163608 7581933 11004695 7519826 9578088 16081784 16522544 12139737
48	CR2	Complement C3d Receptor 2	Protein Coding	10.07	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	8209868
49	TLR9	Toll Like Receptor 9	Protein Coding	9.91	DISEASES inferred ¹⁵ ¹⁵
50	SPN	Sialophorin	Protein Coding	9.89	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	8055109

Sources

Variations for Lymphoma, Non-Hodgkin, Familial

UniProtKB/Swiss-Prot genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

⁷⁵

#	Symbol	AA change	Variation ID	SNP ID
1	BRAF	p.Gly469Ala	VAR_018620	rs121913355
2	BRAF	p.Gly469Arg	VAR_018622	rs121913357
3	BRAF	p.Asp594Gly	VAR_018624	rs121913338
4	CASP10	p.Ala414Val	VAR_037430	rs28936699

ClinVar genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

⁶

(show top 50) (show all 106)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	RAD54B	NM_012415.3(RAD54B): c.1778A> G (p.Asn593Ser)	single nucleotide variant	Pathogenic	rs114216685	GRCh37	Chromosome 8, 95403868: 95403868
2	RAD54B	NM_012415.3(RAD54B): c.1778A> G (p.Asn593Ser)	single nucleotide variant	Pathogenic	rs114216685	GRCh38	Chromosome 8, 94391640: 94391640
3	RAD54L	NM_001142548.1(RAD54L): c.1331T> A (p.Val444Glu)	single nucleotide variant	Pathogenic	rs121908689	GRCh37	Chromosome 1, 46738430: 46738430
4	RAD54L	NM_001142548.1(RAD54L): c.1331T> A (p.Val444Glu)	single nucleotide variant	Pathogenic	rs121908689	GRCh38	Chromosome 1, 46272758: 46272758
5	CASP10	NM_032977.3(CASP10): c.1241C> T (p.Ala414Val)	single nucleotide variant	Pathogenic	rs28936699	GRCh37	Chromosome 2, 202074111: 202074111
6	CASP10	NM_032977.3(CASP10): c.1241C> T (p.Ala414Val)	single nucleotide variant	Pathogenic	rs28936699	GRCh38	Chromosome 2, 201209388: 201209388
7	CASP10	NM_032977.3(CASP10): c.769C> T (p.Gln257Ter)	single nucleotide variant	Pathogenic	rs121909775	GRCh37	Chromosome 2, 202070652: 202070652
8	CASP10	NM_032977.3(CASP10): c.769C> T (p.Gln257Ter)	single nucleotide variant	Pathogenic	rs121909775	GRCh38	Chromosome 2, 201205929: 201205929
9	CASP10	NM_032977.3(CASP10): c.1042_1043insA (p.Gly348Glufs)	insertion	Pathogenic	rs398122800	GRCh37	Chromosome 2, 202073912: 202073913
10	CASP10	NM_032977.3(CASP10): c.1042_1043insA (p.Gly348Glufs)	insertion	Pathogenic	rs398122800	GRCh38	Chromosome 2, 201209189: 201209190
11	TP53	NM_000546.5(TP53): c.722C> T (p.Ser241Phe)	single nucleotide variant	Likely pathogenic	rs28934573	GRCh37	Chromosome 17, 7577559: 7577559
12	TP53	NM_000546.5(TP53): c.722C> T (p.Ser241Phe)	single nucleotide variant	Likely pathogenic	rs28934573	GRCh38	Chromosome 17, 7674241: 7674241
13	TP53	NM_000546.5(TP53): c.844C> T (p.Arg282Trp)	single nucleotide variant	Pathogenic	rs28934574	GRCh37	Chromosome 17, 7577094: 7577094
14	TP53	NM_000546.5(TP53): c.844C> T (p.Arg282Trp)	single nucleotide variant	Pathogenic	rs28934574	GRCh38	Chromosome 17, 7673776: 7673776
15	PRF1	NM_001083116.2(PRF1): c.1122G> A (p.Trp374Ter)	single nucleotide variant	Pathogenic	rs104894176	GRCh37	Chromosome 10, 72358355: 72358355
16	PRF1	NM_001083116.2(PRF1): c.1122G> A (p.Trp374Ter)	single nucleotide variant	Pathogenic	rs104894176	GRCh38	Chromosome 10, 70598599: 70598599
17	NRAS	NM_002524.4(NRAS): c.37G> C (p.Gly13Arg)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121434595	GRCh37	Chromosome 1, 115258745: 115258745
18	NRAS	NM_002524.4(NRAS): c.37G> C (p.Gly13Arg)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121434595	GRCh38	Chromosome 1, 114716124: 114716124
19	NRAS	NM_002524.4(NRAS): c.38G> A (p.Gly13Asp)	single nucleotide variant	Pathogenic	rs121434596	GRCh37	Chromosome 1, 115258744: 115258744
20	NRAS	NM_002524.4(NRAS): c.38G> A (p.Gly13Asp)	single nucleotide variant	Pathogenic	rs121434596	GRCh38	Chromosome 1, 114716123: 114716123
21	BRAF	NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg)	single nucleotide variant	Pathogenic	rs121913357	GRCh37	Chromosome 7, 140481403: 140481403
22	BRAF	NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg)	single nucleotide variant	Pathogenic	rs121913357	GRCh38	Chromosome 7, 140781603: 140781603
23	BRAF	NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala)	single nucleotide variant	Pathogenic	rs121913355	GRCh37	Chromosome 7, 140481402: 140481402
24	BRAF	NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala)	single nucleotide variant	Pathogenic	rs121913355	GRCh38	Chromosome 7, 140781602: 140781602
25	BRAF	NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly)	single nucleotide variant	Pathogenic	rs121913338	GRCh37	Chromosome 7, 140453154: 140453154
26	BRAF	NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly)	single nucleotide variant	Pathogenic	rs121913338	GRCh38	Chromosome 7, 140753354: 140753354
27	EZH2	NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe)	single nucleotide variant	Likely pathogenic	rs267601394	GRCh37	Chromosome 7, 148508727: 148508727
28	EZH2	NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe)	single nucleotide variant	Likely pathogenic	rs267601394	GRCh38	Chromosome 7, 148811635: 148811635
29	EZH2	NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe)	single nucleotide variant	Likely pathogenic	rs267601394	NCBI36	Chromosome 7, 148139660: 148139660
30	EZH2	NM_004456.4(EZH2): c.1936T> C (p.Tyr646His)	single nucleotide variant	Likely pathogenic	rs267601395	GRCh37	Chromosome 7, 148508728: 148508728
31	EZH2	NM_004456.4(EZH2): c.1936T> C (p.Tyr646His)	single nucleotide variant	Likely pathogenic	rs267601395	GRCh38	Chromosome 7, 148811636: 148811636
32	EZH2	NM_004456.4(EZH2): c.1936T> C (p.Tyr646His)	single nucleotide variant	Likely pathogenic	rs267601395	NCBI36	Chromosome 7, 148139661: 148139661
33	TP53	NM_000546.5(TP53): c.844C> G (p.Arg282Gly)	single nucleotide variant	Pathogenic	rs28934574	GRCh37	Chromosome 17, 7577094: 7577094
34	TP53	NM_000546.5(TP53): c.844C> G (p.Arg282Gly)	single nucleotide variant	Pathogenic	rs28934574	GRCh38	Chromosome 17, 7673776: 7673776
35	TP53	NM_000546.5(TP53): c.722C> G (p.Ser241Cys)	single nucleotide variant	Likely pathogenic	rs28934573	GRCh37	Chromosome 17, 7577559: 7577559
36	TP53	NM_000546.5(TP53): c.722C> G (p.Ser241Cys)	single nucleotide variant	Likely pathogenic	rs28934573	GRCh38	Chromosome 17, 7674241: 7674241
37	TP53	NM_000546.5(TP53): c.845G> A (p.Arg282Gln)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs730882008	GRCh37	Chromosome 17, 7577093: 7577093
38	TP53	NM_000546.5(TP53): c.845G> A (p.Arg282Gln)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs730882008	GRCh38	Chromosome 17, 7673775: 7673775
39	NRAS	NM_002524.4(NRAS): c.38G> T (p.Gly13Val)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121434596	GRCh37	Chromosome 1, 115258744: 115258744
40	NRAS	NM_002524.4(NRAS): c.38G> T (p.Gly13Val)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121434596	GRCh38	Chromosome 1, 114716123: 114716123
41	MAP2K1	NM_002755.3(MAP2K1): c.171G> C (p.Lys57Asn)	single nucleotide variant	Likely pathogenic	rs869025608	GRCh37	Chromosome 15, 66727455: 66727455
42	MAP2K1	NM_002755.3(MAP2K1): c.171G> C (p.Lys57Asn)	single nucleotide variant	Likely pathogenic	rs869025608	GRCh38	Chromosome 15, 66435117: 66435117
43	EZH2	NM_004456.4(EZH2): c.1936T> A (p.Tyr646Asn)	single nucleotide variant	Likely pathogenic	rs267601395	GRCh37	Chromosome 7, 148508728: 148508728
44	EZH2	NM_004456.4(EZH2): c.1936T> A (p.Tyr646Asn)	single nucleotide variant	Likely pathogenic	rs267601395	GRCh38	Chromosome 7, 148811636: 148811636
45	EZH2	NM_004456.4(EZH2): c.1937A> C (p.Tyr646Ser)	single nucleotide variant	Likely pathogenic	rs267601394	GRCh37	Chromosome 7, 148508727: 148508727
46	EZH2	NM_004456.4(EZH2): c.1937A> C (p.Tyr646Ser)	single nucleotide variant	Likely pathogenic	rs267601394	GRCh38	Chromosome 7, 148811635: 148811635
47	MYC	NM_002467.5(MYC): c.218C> T (p.Thr73Ile)	single nucleotide variant	Likely pathogenic	rs756091827	GRCh38	Chromosome 8, 127738435: 127738435
48	MYC	NM_002467.5(MYC): c.218C> T (p.Thr73Ile)	single nucleotide variant	Likely pathogenic	rs756091827	GRCh37	Chromosome 8, 128750681: 128750681
49	B2M	NM_004048.2(B2M): c.3G> A (p.Met1Ile)	single nucleotide variant	Likely pathogenic	rs1057519877	GRCh37	Chromosome 15, 45003747: 45003747
50	B2M	NM_004048.2(B2M): c.3G> A (p.Met1Ile)	single nucleotide variant	Likely pathogenic	rs1057519877	GRCh38	Chromosome 15, 44711549: 44711549

Cosmic variations for Lymphoma, Non-Hodgkin, Familial:

⁹

(show all 31)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM44623	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.487T>A	p.Y163N	17:7675125-7675125	9
2	COSM44571	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.581T>G	p.L194R	17:7674950-7674950	9
3	COSM10894	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.670G>A	p.E224K	17:7674861-7674861	9
4	COSM35908	TNFAIP3	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.2251G>A	p.E751K	6:137881197-137881197	9
5	COSM35907	TNFAIP3	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.2209C>A	p.Q737K	6:137881155-137881155	9
6	COSM35911	TNFAIP3	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.1354G>T	p.E452*	6:137878799-137878799	9
7	COSM35970	TNFAIP3	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.1421C>A	p.T474N	6:137878866-137878866	9
8	COSM35913	TNFAIP3	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.905T>C	p.L302P	6:137877175-137877175	9
9	COSM35969	TNFAIP3	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.503G>A	p.W168*	6:137875704-137875704	9
10	COSM35909	TNFAIP3	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.254G>A	p.W85*	6:137871481-137871481	9
11	COSM6987354	STAG2	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.3688A>G	p.M1230V	23:124100589-124100589	9
12	COSM6945907	PIM1	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.94G>A	p.E32K	6:37170784-37170784	9
13	COSM6975552	PAX5	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.559A>T	p.I187F	9:37002693-37002693	9
14	COSM581	NRAS	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.181C>G	p.Q61E	1:114713909-114713909	9
15	COSM586	NRAS	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.183A>C	p.Q61H	1:114713907-114713907	9
16	COSM562	NRAS	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.34G>T	p.G12C	1:114716127-114716127	9
17	COSM564	NRAS	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.35G>A	p.G12D	1:114716126-114716126	9
18	COSM574	NRAS	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.38G>T	p.G13V	1:114716123-114716123	9
19	COSM566	NRAS	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.35G>T	p.G12V	1:114716126-114716126	9
20	COSM5416033	NFKBIE	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.782+5G>A	p.?	6:44264977-44264977	9
21	COSM499	HRAS	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.182A>G	p.Q61R	11:533874-533874	9
22	COSM6987350	ARID5B	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.793T>G	p.F265V	10:62050947-62050947	9
23	COSM3717661		haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.487T>A	p.Y163N	17:7675125-7675125	9
24	COSM307267		haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.487T>A	p.Y163N	17:7675125-7675125	9
25	COSM307268		haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.487T>A	p.Y163N	17:7675125-7675125	9
26	COSM3717662		haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.487T>A	p.Y163N	17:7675125-7675125	9
27	COSM6987351		haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.64T>G	p.F22V	10:62050947-62050947	9
28	COSM6987353		haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.3799A>G	p.M1267V	23:124100589-124100589	9
29	COSM307269		haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.91T>A	p.Y31N	17:7675125-7675125	9
30	COSM3077774		haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.295T>C	p.C99R	6:394899-394899	9
31	COSM307270		haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma	c.208T>A	p.Y70N	17:7675125-7675125	9

Copy number variations for Lymphoma, Non-Hodgkin, Familial from CNVD:

⁷

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	164351	22	36286416	36295356	Translate	CEP1	Non-Hodgkin''s lymphomas

Sources

Expression for Lymphoma, Non-Hodgkin, Familial

Search GEO for disease gene expression data for Lymphoma, Non-Hodgkin, Familial.

Sources

Pathways for Lymphoma, Non-Hodgkin, Familial

Pathways related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

(show top 50) (show all 57)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	14.06	BCL10 BCL6 BRAF CASP10 CCND1 MALT1
2	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.37	BCL6 BRAF CCND1 MYC NRAS PIK3CA
3	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.88	BRAF CCND1 MYC NRAS PIK3CA TP53
4	Apoptosis Modulation and Signaling ¹ Show member pathways Apoptosis ³⁷ Apoptosis ¹ Apoptosis and survival Apoptotic TNF-family pathways ²² Apoptosis Signaling Pathways ⁶⁵ Death Receptor Signaling ⁶⁷	12.81	CASP10 MYC NRAS PIK3CA PRF1 TP53
5	IL-2 Pathway ⁶⁴ Show member pathways HMGB1 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TREM1 Pathway ⁶⁴	12.8	BCL10 BRAF MALT1 MYC NRAS PTPRC
6	Pathways in cancer ³⁷	12.76	ALK BRAF CCND1 MYC NRAS PIK3CA
7	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.75	ALK BRAF CCND1 NRAS PIK3CA TP53
8	Downstream signaling events of B Cell Receptor (BCR) ⁶⁶ Show member pathways Activation of RAS in B cells ⁶⁶ Signaling by the B Cell Receptor (BCR) ⁶⁶	12.74	BCL10 MALT1 NRAS PIK3CA TP53
9	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.74	BRAF CCND1 MYC NRAS PIK3CA TP53
10	Development HGF signaling pathway ²² Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development Neurotrophin family signaling ²² MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ Neurotrophin signaling pathway ³⁷ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.72	BRAF NPM1 NRAS PIK3CA TP53
11	NF-kappaB Signaling ⁴	12.57	BCL10 BCL6 MALT1 PAX5 PTPRC
12	Kaposi's sarcoma-associated herpesvirus infection ³⁷ Show member pathways Hepatitis B ³⁷	12.53	CASP10 CCND1 MYC NRAS PIK3CA TP53
13	MicroRNAs in cancer ³⁷	12.52	CCND1 MYC NRAS PIK3CA TP53
14	Apoptosis Pathway ⁷² Show member pathways Akt Pathway ⁷² NF-kappaB Pathway ⁷²	12.44	CASP10

Lymphoma, Non-Hodgkin, Familial

Aliases & Classifications for Lymphoma, Non-Hodgkin, Familial

MalaCards integrated aliases for Lymphoma, Non-Hodgkin, Familial:

Classifications:

External Ids:

Summaries for Lymphoma, Non-Hodgkin, Familial

Related Diseases for Lymphoma, Non-Hodgkin, Familial

Diseases related to Lymphoma, Non-Hodgkin, Familial via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Lymphoma, Non-Hodgkin, Familial:

Symptoms & Phenotypes for Lymphoma, Non-Hodgkin, Familial

Clinical features from OMIM:

Human phenotypes related to Lymphoma, Non-Hodgkin, Familial:

GenomeRNAi Phenotypes related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Lymphoma, Non-Hodgkin, Familial:

Drugs & Therapeutics for Lymphoma, Non-Hodgkin, Familial

FDA approved drugs:

Drugs for Lymphoma, Non-Hodgkin, Familial (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Cell-based therapeutics:

Genetic Tests for Lymphoma, Non-Hodgkin, Familial

Anatomical Context for Lymphoma, Non-Hodgkin, Familial

MalaCards organs/tissues related to Lymphoma, Non-Hodgkin, Familial:

Publications for Lymphoma, Non-Hodgkin, Familial

Articles related to Lymphoma, Non-Hodgkin, Familial:

Genes for Lymphoma, Non-Hodgkin, Familial

Genes related to Lymphoma, Non-Hodgkin, Familial (8 elite genes):

Variations for Lymphoma, Non-Hodgkin, Familial

UniProtKB/Swiss-Prot genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

ClinVar genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

Cosmic variations for Lymphoma, Non-Hodgkin, Familial:

Copy number variations for Lymphoma, Non-Hodgkin, Familial from CNVD:

Expression for Lymphoma, Non-Hodgkin, Familial

Pathways for Lymphoma, Non-Hodgkin, Familial

Pathways related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :